UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development

Biomedicines, 2021-09, Vol.9 (9), p.1277

2021

Volltextzugriff (PDF)

Evaluation of Cytochrome P450 3A4-Mediated Drug–Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation

Clinical pharmacokinetics, 2016-11, Vol.55 (11), p.1435-1445

2016

Volltextzugriff (PDF)

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

Molecular pharmaceutics, 2013-11, Vol.10 (11), p.4055-4062

2013

Volltextzugriff (PDF)

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

Cancer chemotherapy and pharmacology, 2021-12, Vol.88 (6), p.921-930

2021

Volltextzugriff (PDF)

A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens

Clinica chimica acta, 2008-12, Vol.398 (1), p.105-112

2008

Volltextzugriff (PDF)

A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer

Biopharmaceutics & drug disposition, 2013-04, Vol.34 (3), p.141-154

2013

Volltextzugriff (PDF)

Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)

The American journal of cardiology, 2017-05, Vol.119 (10), p.1576-1583

2017

Volltextzugriff (PDF)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-10, Vol.11 (10), p.e005829

2023

Volltextzugriff (PDF)

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors

Clinical and translational science, 2024-03, Vol.17 (3), p.e13769-n/a

2024

Volltextzugriff (PDF)

Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs

Current medicinal chemistry, 2008-04, Vol.15 (8), p.809-825

2008

Volltextzugriff (PDF)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

CPT: pharmacometrics and systems pharmacology, 2023-01, Vol.12 (1), p.95-109

2023

Volltextzugriff (PDF)

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

Cancer chemotherapy and pharmacology, 2015-11, Vol.76 (5), p.917-924

2015

Volltextzugriff (PDF)

A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9

Clinical cardiology (Mahwah, N.J.), 2017-07, Vol.40 (7), p.503-511

2017

Volltextzugriff (PDF)

Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects

The AAPS journal, 2011-12, Vol.13 (4), p.650-661

2011

Volltextzugriff (PDF)

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9

The AAPS journal, 2015-07, Vol.17 (4), p.881-890

2015

Volltextzugriff (PDF)

Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

CPT: pharmacometrics and systems pharmacology, 2021-10, Vol.10 (10), p.1221-1235

2021

Volltextzugriff (PDF)

A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents

Journal of antimicrobial chemotherapy, 2008-11, Vol.62 (5), p.1037-1045

2008

Volltextzugriff (PDF)

Gastric Reacidification with Betaine HCl in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria

Molecular pharmaceutics, 2013-11, Vol.10 (11), p.4032-4037

2013

Volltextzugriff (PDF)

A simple in vitro PK/PD model system to determine time–kill curves of drugs against Mycobacteria

Tuberculosis (Edinburgh, Scotland), 2009-09, Vol.89 (5), p.378-385

2009

Volltextzugriff (PDF)

Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis

Toxicological sciences, 2012-11, Vol.130 (1), p.205-213

2012

Volltextzugriff (PDF)

Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study

mAbs, 2014-11, Vol.6 (6), p.1500-1508

2014

Volltextzugriff (PDF)

Pharmacokinetically-Guided Lead Optimization of Nitrofuranylamide Anti-Tuberculosis Agents

The AAPS journal, 2008, Vol.10 (1), p.157-165

2008

Volltextzugriff (PDF)

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

The lancet oncology, 2018-03, Vol.19 (3), p.310-322

2018

Volltextzugriff (PDF)

Abstract CT253: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT253-CT253

2020

Volltextzugriff (PDF)

A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies

Blood, 2019-11, Vol.134 (Supplement_1), p.1289-1289

2019

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(48)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development

Evaluation of Cytochrome P450 3A4-Mediated Drug–Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation

Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development

Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens

A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer

Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)

AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors

Biopharmaceutics, pharmacokinetics and pharmacodynamics of antituberculosis drugs

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

A phase 1 study to evaluate the safety and LDL cholesterol–lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9

Comparative Performance of Cell Life Span and Cell Transit Models for Describing Erythropoietic Drug Effects

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9

Population repeated time‐to‐event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents

Gastric Reacidification with Betaine HCl in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria

A simple in vitro PK/PD model system to determine time–kill curves of drugs against Mycobacteria

Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis

Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study

Pharmacokinetically-Guided Lead Optimization of Nitrofuranylamide Anti-Tuberculosis Agents

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Abstract CT253: Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors

A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies

Suchergebnisse filtern